TympaHealth Technologies Ltd
TympaHealth Technologies Ltd is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at TympaHealth Technologies Ltd.
TympaHealth Technologies Ltd is a company.
Key people at TympaHealth Technologies Ltd.
TympaHealth Technologies Ltd develops the Tympa system, a patented mobile ear care kit enabling comprehensive ear and hearing health assessments, including examinations, wax removal via microsuction, and diagnostics, integrated with a secure digital patient record system.[1][2][3] It serves patients in community settings like pharmacies, care homes, opticians, primary care, NHS Trusts, and private audiology clinics, addressing accessibility barriers by reducing outpatient wait times, enabling earlier disease detection, and lowering costs compared to traditional pathways.[1][3] The company has screened over 250,000 patients across UK NHS and private sectors, with strong growth evidenced by $31M total funding (including a recent $23M round and $8M seed), 27 employees, and $7.9M revenue, positioning it for expansion into the US, Netherlands, and beyond.[1][2]
Founded in 2017 as CEEK HEALTH LIMITED (renamed Tympa Health Technologies Limited in 2019), the company emerged from Dr. Krishan Ramdoo's experience as an ENT surgeon.[3][4][5] Starting his medical career at Oxford University Hospitals in 2009, Ramdoo trained in London, earned a PhD at University College London (UCL), and identified critical gaps in ear and hearing care access amid rising hearing loss impacts.[3][5] This led him to create TympaHealth, uniting doctors, audiologists, ENT specialists, physicists, and machine learning experts to deliver community-based solutions.[3] Early traction included NHS adoption for elective recovery (featured in NHSX playbooks), a UK-first teleotology platform at UCLH Hospital, and pharmacy triage pathways reducing wait times and costs.[1]
TympaHealth rides the digital health and out-of-hospital care wave, transforming ear and hearing services from hospital-centric models to community-accessible ones amid NHS backlogs and global hearing loss affecting 1.5B people.[1][3] Timing aligns with post-pandemic elective recovery demands, telehealth acceleration, and cost pressures on integrated care systems (ICS), where its pharmacy triage pathways demonstrate significant savings and reduced clinician burden.[1] It influences the ecosystem by pioneering models like UCLH's teleotology, setting precedents for primary care screening in audiology-starved areas, and exporting to underserved markets like the US, amplifying scalable, tech-enabled preventive care.[1][2]
With $31M raised and US foothold via dedicated operations, TympaHealth is primed for explosive growth through pharmacy chains, care homes, and international health systems, potentially dominating accessible hearing diagnostics.[2][5] Trends like AI diagnostics, aging populations, and value-based care will propel it, evolving from UK NHS pioneer to global leader—watch for partnerships with US payers and further research validating outcomes. This builds on its core mission: making ear health as routine as a check-up, directly tackling the accessibility crisis Dr. Ramdoo first witnessed.
Key people at TympaHealth Technologies Ltd.
